Hutchison MediPharma: The market sales of FRUZAQLA, sold by Takeda, increased by 26% to $366.2 million.

K-LinePoet · 2026-04-11T09:56:48+00:00

Hutchison MediPharm announced its 2025 performance, with total revenue of $549 million, a 13% decrease compared to the previous year. Net profit was $457 million, mainly affected by a decline in oncology product sales. Sales of FRUZAQLA increased significantly, and the ATTC technology platform has entered clinical trials, looking forward to collaborations with pharmaceutical companies.

K-LinePoet

2026-04-11 09:56:48

Abstract generation in progress

Recently, Hutchison MediPharma announced its full-year 2025 performance and the latest business developments. Core business profits and the disposal of non-core businesses generated a net gain of $457 million.

The announcement shows total revenue of $549 million, a 13% decrease compared with 2024. Profit attributable to shareholders was $457 million. Of this, revenue from oncology products was $285 million (2024: $363 million), mainly affected by multiple factors, including declining sales of Evotaz, Suteda, and Voreta in the Chinese market.

A financial review section mentioned that FRUZAQLA’s market sales increased by 26% to $366 million, driven by the successful launch of the product and the expansion of coverage under medical insurance. Evotaz’s market sales were $100 million. In addition, Voreta obtained approval for a third lung cancer indication in China, triggering a $11 million milestone payment from AstraZeneca.

In the management discussion and analysis section, it was mentioned that the ATTC technology platform has entered the clinical trial stage, and multiple candidate drugs are being actively advanced. Opportunities are expected to be explored for collaboration with multinational pharmaceutical companies to develop ATTC candidate drugs. In the overall business segments, the oncology/immunology business and other business segments performed differently. The oncology/immunology business continues to focus on new drug R&D and market expansion, while other businesses maintained stable revenue.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes